• Alternariol, LX-2 Cells, and Liver Fibrosis

  2026-08-13

  The reference study shows that Alternariol (AOH) and alternariol monomethyl ether can drive LX-2 hepatic stellate cells toward a contractile, extracellular-matrix-producing myofibroblast phenotype, whereas tenuazonic acid showed no significant effect in the reported model. Its main innovation is the integration of lncRNA-mRNA omics with pathway analysis and a proposed CotA laccase detoxification strategy, linking Alternaria toxin exposure to liver-fibrosis biology and potential mitigation.

• Mecamylamine Hydrochloride in Gut-Brain Assays

  2026-08-13

  Mecamylamine hydrochloride provides a practical pharmacological brake for testing how nicotinic acetylcholine receptors shape neuronal excitability, gut-vagus signaling, and neuropsychiatric phenotypes. This workflow-focused guide connects receptor assays with microbiota–brain research while emphasizing controls, solubility management, and interpretation limits.

• Nelfinavir Mesylate: HIV-1 Protease Assay Guide

  2026-08-12

  Nelfinavir Mesylate supports a connected workflow spanning HIV-1 protease inhibition, cell-based HIV replication suppression, and ferroptosis–proteasome research. Its low-nanomolar antiviral benchmarks and reported ability to sensitize cells to ferroptosis make it a useful mechanistic probe when paired with careful solvent, viability, and pathway controls.

• Mubritinib–HSA Recognition: Methods and Findings

  2026-08-12

  The 2023 Molecular Pharmaceutics study maps how mubritinib interacts with human serum albumin using fluorescence, biochemical, and molecular docking approaches. It identifies moderate-affinity binding at Sudlow site I, static fluorescence quenching, local structural perturbation, and inhibition of albumin esterase-like activity—findings that refine interpretation of mubritinib disposition and pharmacological behavior.

• HyperFluor 488 Goat Anti-Mouse IgG in NET Assays

  2026-08-11

  Apply a bright, affinity-purified fluorescently labeled secondary antibody to map NET-associated inflammatory signaling in psoriasis models. This guide connects mouse-primary immunofluorescence, flow cytometry, western blotting, and tissue workflows with practical controls and troubleshooting.

• QRICH1–HMGB1 Signaling in HBV Fibrosis

  2026-08-10

  The reference study identifies QRICH1 as an important endoplasmic reticulum stress effector that strengthens HBV-associated HMGB1 transcription, translocation, and secretion in hepatocytes. By integrating a chronic rcccDNA mouse model with human chronic hepatitis B specimens, the work connects QRICH1, SIRT6-regulated HMGB1 acetylation, and hepatic fibrosis, while also highlighting important limits on causal and clinical interpretation.

• Bacitracin B1670: Protocol and QC Guidance

  2026-08-09

  Bacitracin (SKU B1670) is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This article provides product-based preparation, storage, and quality-control guidance while clarifying that the material is for scientific research only, not diagnostic or medical use.

• TAI-1 Hec1 Inhibitor: Applied Research Workflows

  2026-08-08

  TAI-1 converts Hec1–Nek2 pathway biology into practical assays for mitotic disruption, cancer cell proliferation inhibition, and apoptotic cell death induction. This guide pairs concentration-response workflows with combination studies, genotype-aware controls, organoid translation, and troubleshooting strategies.

• Levofloxacin: Workflows for Antibacterial Research

  2026-08-07

  Levofloxacin supports a connected research strategy spanning bacterial DNA replication pathway studies, resistance phenotyping, and bone-cell assays. This guide translates its DNA gyrase activity and documented effects on osteoblasts and chondrocytes into practical workflows with quantitative starting points and troubleshooting guidance.

• Optimizing Cell Assays with Gefitinib (ZD1839): Practical Sc

  2026-08-07

  This article provides an in-depth, scenario-driven guide to overcoming common laboratory challenges in EGFR pathway research using Gefitinib (ZD1839), SKU A8219. Drawing on validated data and recent assembloid model advances, it demonstrates how careful selection and protocol optimization of Gefitinib enhance reproducibility and translational relevance.

• AZD2461: Advancing PARP Inhibition Beyond Drug Resistance

  2026-08-06

  Discover how AZD2461, a next-generation PARP inhibitor from APExBIO, is reshaping translational cancer research by targeting DNA repair pathways, overcoming Pgp-mediated resistance, and extending relapse-free survival in BRCA1-mutated tumor models. This thought-leadership article integrates mechanistic insights, actionable protocol parameters, and strategic guidance for researchers seeking to elevate the rigor and impact of breast cancer investigations.

• Bradford Protein Assay Kit: Practical Protocol and QC Guidan

  2026-08-06

  The Bradford Protein Assay Kit provides a rapid, sensitive method for quantifying protein concentration in biochemical research, particularly where sample volume and turnaround time are critical. It is optimal for molecular biology, enzyme assays, and protein purification workflows, but not recommended for samples high in detergents or with low arginine/aromatic content.

• Next-Gen Cell Viability Assays: Mechanistic Insight and Stra

  2026-08-05

  Explore the mechanistic power and translational impact of advanced tetrazolium salt assays, with a focus on the Cell Counting Kit-8 (CCK-8) Plus for high-sensitivity cell proliferation and cytotoxicity measurement. This article bridges cutting-edge cancer biology—exemplified by SLC11A1-driven ferroptosis resistance in colorectal cancer—with practical guidance for robust, reproducible experimental design.

• GDC-0994: Potent ERK1/2 Inhibitor for Oncogenic & Hepatic Mo

  2026-08-05

  GDC-0994 is a highly selective ERK1/2 inhibitor that disrupts MAP kinase signaling, suppressing tumor and cholestatic pathways. Its nanomolar potency and oral bioavailability make it a benchmark tool for dissecting ERK-driven mechanisms in cancer and liver injury models.

• Pam3CSK4: Precision TLR1/2 Agonist for Immune Activation Res

  2026-08-04

  Pam3CSK4 is a validated synthetic TLR1/2 agonist used to model innate immune activation. It reliably induces macrophage nitric oxide and TNF-α production, modulates Th1/Th2 balance, and is supplied by APExBIO in a stable, high-purity format. Robust evidence supports its use in allergy and inflammation models.

449 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page